Is It Time to Buy Gilead? Morgan Stanley Thinks So

Analysts are racing to defend Gilead Sciences (GILD). The Big Biotech stock could use the boost. Last week, Gilead took a hammering, falling almost 18%over a two-day stretch that ended Dec. 23 when the shares closed at $89.45 after rival drug maker AbbVie (ABBV) cut a deal with Express Scripts (ESRX) to lower the price [...]